Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Noemí Reguart
Antagonistic SMAD2/3 control of TIMP-1, VEGF-A, and hypoxia signaling in myofibroblasts shapes histotype-specific angiogenesis in lung cancer
Abstract Non-small cell lung cancer (NSCLC) exhibits disparate responses to anti-angiogenic therapies between its two major histologic subtypes, lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), suggesting a histotype-dependent angiogenesis regulation. Tumor-associated fibroblasts (TAFs) exhibit an activated/myofibroblast-like phenotype in NSCLC, and are emerging as major regulators of tumor progression; yet, their role in controlling angiogenesis in NSCLC remains undefined.
Día Mundial del Cáncer de Pulmón: un futuro de esperanza gracias a la investigación y los avanc
En los últimos años, el tratamiento del cáncer de pulmón ha experimentado una auténtica revolución. Lo que hasta hace poco era una enfermedad con opciones limitadas se ha transformado en un campo donde los avances científicos y la innovación terapéutica han permitido mejorar de forma significativa la supervivencia y la calidad de vida de los pacientes.
Dia Mundial del Càncer de Pulmó: un futur d’esperança gràcies a la recerca i als avenços terapè
En els darrers anys, el tractament del càncer de pulmó ha viscut una autèntica revolució. Allò que fins fa poc era una malaltia amb opcions limitades s’ha transformat en un camp on els avenços científics i la innovació terapèutica han permès millorar significativament la supervivència i la qualitat de vida dels pacients.
World Lung Cancer Day: a future of hope driven by research and therapeutic advances
In recent years, lung cancer treatment has undergone a genuine revolution. What was once a disease with limited therapeutic options has become a field where scientific breakthroughs and therapeutic innovation have significantly improved patients’ survival and quality of life. Groundbreaking advances in lung cancer treatment This progress has been made possible thanks to an increasingly precise understanding of tumour biology and the incorporation of targeted therapies and immunotherapy.
A cross-sectional analysis of treatment patterns in small-cell lung cancer in five European countries
Lung cancer is the leading cause of cancer-related mortality worldwide [1]. Small-cell lung cancer (SCLC) is an aggressive, high-grade cancer that accounts for 15% of all lung cancers [2]. In Europe, the estimated prevalence of SCLC is 1–5 per 10,000 people [3,4]. Approximately two-thirds of patients present with extensive-stage SCLC (ES-SCLC) at the time of primary diagnosis [5].
Lung Cancer in Spain
Lung Cancer Epidemiology and Tobacco Use in Spain Lung cancer is the fourth most common cancer diagnosed in Spain in both sexes, after colorectal, prostate, and breast cancers (Table 1), with a 5-year survival of 12.7% in men and 17.6% in women reported for the period 2008 to 2013. In 2019, the incidence of lung cancer in Spain was 29,053 cases (22,083 in men and 7420 in women). 1 Sociedad Española de Oncologia Médica Las cifras del cáncer en españa 2020.
PD-L1 expression testing in non-small cell lung cancer
Comparison and standardization of different PD-L1 IHC platforms As outlined before, several reproducible PD-L1 assays have been developed for each of the immune-inhibitors (Table 2). This is leading to the paradoxical situation where the pathologists must select between different antibodies and assay conditions according to the prescription of a drug, rather than focusing on the accuracy of the technique itself.
Using biomarkers to determine optimal combinations with immunotherapy (biomarker discovery perspective)
Metrics Downloaded 54 times History Received 27 February 2020 Accepted 1 May 2020 Published online 14 May 2020 Published in print August 2020 Information © 2020 Future Medicine Ltd KeywordsFinancial & competing interests disclosure This paper was funded in part by Ministry of Health, Instituto de Salud Carlos III (FIS PI16/00890), Novartis Pharma and Pfizer.
Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.
Article Tools Lung Cancer—Non-Small Cell Metastatic Juergen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Toyoaki Hida, Maja J. De Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre Jean Souquet, Johan F. Vansteenkiste, Monica Giovannini, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Rebecca Suk Heist Show More Lung Cancer Group Cologne, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Dept.
Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?
Article in Press Jordi Remon , MD a , Noemí Reguart x Search for articles by this author Affiliations Hospital Clínic i Provincial de Barcelona, Medical Oncology Department, Barcelona, Spain Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain , MD, PhD b,c , Edouard Auclin , MD d , Benjamin Besse x Search for articles by this author Affiliations Gustave Roussy, Cancer Medicine Department,...
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Therapeutics, Targets, and Chemical Biology Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma Aleix Prat, Alejandro Navarro, Laia Paré, Noemí Reguart, Patricia Galván, Tomás Pascual, Alex Martínez, Paolo Nuciforo, Laura Comerma, Llucia Alos, Nuria Pardo, Susana Cedrés, Cheng Fan, Joel S. Parker, Lydia Gaba, Iván Victoria, Nuria Viñolas, Ana Vivancos, Ana Arance and Enriqueta Felip
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Noemí
Contact Noemí, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack